Literature DB >> 12925011

The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.

F Galeffi1, L Bianchi, J P Bolam, L Della Corte.   

Abstract

The loss of dopaminergic neurons of the substantia nigra in Parkinson's disease and in animal models of Parkinson's disease is associated with an imbalance in the activity of the so-called 'direct' and 'indirect' pathways of information flow through the basal ganglia. The aim of the present study was to determine whether the imbalance is reflected in changes in the release of GABA, aspartate and glutamate in the pathways using dual probe microdialysis in freely moving rats. Control and 6-hydroxydopamine-(6-OHDA)-lesioned rats were implanted with microdialysis probes in the neostriatum and substantia nigra or globus pallidus and the release of amino acids was analysed in the dialysates. Basal levels of amino acids were largely unaltered by the 6-OHDA lesion; however, the levels of GABA in the globus pallidus dialysates were significantly elevated in the lesioned rats, indicating an imbalance in favour of the indirect pathway. Administration of kainic acid to the neostriatum enhanced the release of GABA locally and in the distal probes in the substantia nigra and globus pallidus. In 6-OHDA-lesioned rats, stimulated release of GABA in the substantia nigra was abolished, indicating a reduction in transmission along the direct pathway. Thus, consistent with the direct-indirect pathway model of the basal ganglia, the 6-OHDA lesion results in an elevation of the basal release of GABA in the striatopallidal (indirect) pathway and a reduction in the evoked release of GABA in the striatonigral (direct) pathway. These imbalances may underlie, at least in part, the motor abnormalities of Parkinson's disease and in animal models of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925011     DOI: 10.1046/j.1460-9568.2003.02795.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  14 in total

1.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

Review 2.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

3.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Karen L Eskow Jaunarajs; Thomas Button; Lisa M Savage; William Wolf; Christopher Bishop
Journal:  Exp Neurol       Date:  2011-02-22       Impact factor: 5.330

4.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

5.  Localization and function of GABA transporters in the globus pallidus of parkinsonian monkeys.

Authors:  Adriana Galvan; Xing Hu; Yoland Smith; Thomas Wichmann
Journal:  Exp Neurol       Date:  2010-02-04       Impact factor: 5.330

6.  Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Authors:  Orhan Tansel Korkmaz; Neşe Tunçel; Muzaffer Tunçel; Elif Mine Oncü; Varol Sahintürk; Mustafa Celik
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

Review 7.  The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Eric Plitman; Philip Gerretsen; Jun Ku Chung; Yusuke Iwata; Ariel Graff-Guerrero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-09-01       Impact factor: 5.067

8.  Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Twum A Ansah
Journal:  Neurochem Int       Date:  2014-04-04       Impact factor: 3.921

9.  Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease.

Authors:  Rosa M Villalba; Yoland Smith
Journal:  Front Syst Neurosci       Date:  2011-08-23

10.  Striatal glutamate release in L-DOPA-induced dyskinetic animals.

Authors:  Nina Nevalainen; Martin Lundblad; Greg A Gerhardt; Ingrid Strömberg
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.